key: cord-0713877-epz2riyn
authors: Cardoso, F.; Paluch-Shimon, S.; Senkus, E.; Curigliano, G.; Aapro, M.S.; André, F.; Barrios, C.H.; Bergh, J.; Bhattacharyya, G.S.; Biganzoli, L.; Boyle, F.; Cardoso, M.-J.; Carey, L.A.; Cortés, J.; El Saghir, N.S.; Elzayat, M.; Eniu, A.; Fallowfield, L.; Francis, P.A.; Gelmon, K.; Gligorov, J.; Haidinger, R.; Harbeck, N.; Hu, X.; Kaufman, B.; Kaur, R.; Kiely, B.E.; Kim, S.-B.; Lin, N.U.; Mertz, S.A.; Neciosup, S.; Offersen, B.V.; Ohno, S.; Pagani, O.; Prat, A.; Penault-Llorca, F.; Rugo, H.S.; Sledge, G.W.; Thomssen, C.; Vorobiof, D.A.; Wiseman, T.; Xu, B.; Norton, L.; Costa, A.; Winer, E.P.
title: 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)(†)
date: 2020-09-23
journal: Ann Oncol
DOI: 10.1016/j.annonc.2020.09.010
sha: 74bc9e2a4ff7dedcc232b0d8f01eb074ed20f367
doc_id: 713877
cord_uid: epz2riyn

• This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients; • It provides updates on the management of patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care; • Updated diagnostic and treatment algorithms are also provided; • All recommendations were compiled by a multidisciplinary group of international experts; • Recommendations are based on available clinical evidence and the collective expert opinion of the authors.

For the purpose of ABC guidelines, advanced breast cancer (ABC) comprises both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). 1, 2 Advanced/metastatic breast cancer remains a virtually incurable disease, with a median overall survival (OS) of about 3 years and a 5-year survival rate of around 25%, 3, 4 even in countries without major accessibility problems. Survival is strongly related to breast cancer subtype, with the major advances seen in human epidermal growth factor receptor 2 (HER2)positive ABC. [5] [6] [7] [8] [9] ABC is a treatable disease with several available therapies and many others in development. However, their impact on survival and quality of life (QoL) of ABC patients has been slow 3 and different for de novo versus recurrent ABC, with the latter becoming much harder to treat in recent years. 10 Outcomes are also strongly related to access to the best available care, which includes not only the most efficacious medicines, but also multidisciplinary, specialised care, implementation of guidelines, high quality pathology, imaging and radiotherapy (RT). Lack of any of these crucial pillars of modern oncological care inevitably results in substantially worse outcomes, as exemplified in the New Zealand report "I am still here". 11 While mortality rates have decreased in the majority of developed countries, most deaths are currently seen in less developed societies, and access issues explain the majority of these inequalities. 12 The application of the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) 13 to the field of ABC 14 shows that the quality of clinical research has improved over the last decade and that better therapies have been developed, providing hope that a substantial improvement in the median OS of ABC patients might soon be seen. However, some clinically relevant questions are still unanswered and may be difficult to address through traditional clinical trials, such as the best sequence of therapies for each individual patient. The application of computer analytics to big data and real-word data is one of the potential ways forward. In depth discussion must take place regarding the impact of this 'new' level of evidence (LoE) into current treatment guidelines and their integration with clinical trial data.

corrections on content and wording. A final set of recommendations was presented, discussed and voted upon during the consensus session of ABC 5. All panel members were instructed to vote on all questions, and any members with a potential conflict of interest or who did not feel comfortable answering the question (e.g. due to lack of expertise in a particular field) were instructed to vote 'abstain'. Additional changes in the wording of statements were made during the session. As some important studies were presented a few weeks later at the 2019 San Antonio Breast Cancer Symposium, particularly for new anti-HER2 therapies, three additional statements were developed after the ABC 5 conference, circulated for revision and voted by all panel members. Statements related to the management of side effects and difficult symptoms, included under the supportive and palliative care section, were not voted on during the consensus session, but were discussed and unanimously agreed by email, and are therefore considered to have 100% consensus agreement. Previous ABC recommendations that did not require update or only minor changes were not re-voted but were reviewed by all panel members by email and remain valid. To provide a full overview of all ABC guidelines currently approved, this manuscript includes a list of all recommendations per subject, highlighting those that were discussed, voted and approved in ABC 5. However, this manuscript only describes the evidence for newly developed or updated guidelines. We refer the reader to the manuscripts of previous ABC guidelines for the detailed explanation of guidelines not updated/added during ABC 5. Table S2 , available at Annals of Oncology online, describes the LoE and GoR system used, 15 Adequate OFS for ABC premenopausal patients can be obtained through bilateral ovariectomy, continuous use of LHRH agonists or OFA through pelvic RT (the latter is not always effective and therefore is the least preferred option).

If an LHRH agonist is used in this age group, it should usually be given on a q4w basis to optimise OFS.

Efficacy of OFS must be initially confirmed analytically through serial evaluations of serum oestradiol, even in the presence of amenorrhoea, especially if an AI is administered.

As all endocrine interventions for premenopausal patients with endocrine-responsive ABC require indefinite OFS, choosing one method over the other requires a balance of the patient's wish for potentially preserving fertility, compliance with frequent injections over a long period of time, risk of inadequate oestrogen level suppression and cost. J o u r n a l P r e -p r o o f the highest standards of patient-centred care, as defined by:

• Open communication between patients and their cancer care teams as a primary goal.

• Educating patients about treatment options and supportive care, through development and dissemination of evidence-based information in a clear, culturally appropriate form.

• Encouraging patients to be proactive in their care and to share decision making with their healthcare providers.

• Empowering patients to develop the capability of improving their own QoL within their cancer experience.

• Always taking into account patient preferences, values and needs as essential to optimal cancer care.

• Patients should have easy access to well-designed clinical studies since these are crucial for further improvement in the management of ABC.

Every ABC patient should:

• Have access to the most up-to-date treatments and innovative therapies at accessible breast units/centres.

• Be treated in specialist breast units/centres/services (SBUs) by a specialised multidisciplinary team including specialised side effects management and a nurse experienced in the treatment of ABC.

• Survivorship issues and palliative care should be addressed and offered at an early stage.

• A quality assurance programme covering the entire breast cancer pathway from screening Additionally, attention needs to be paid to collection methods, timing of assessments and handling of missing data. More sophisticated statistics should also be employed to ensure that clinicians have better, reliable data to help patients when choosing between treatment options.

After appropriate informed consent, inclusion of patients in well-designed, prospective, independent trials must be a priority whenever such trials are available and the patient is willing to participate. Misunderstandings about prognosis are common [17] [18] [19] and are associated with increased exposure to futile treatments. [20] [21] [22] [23] Most patients want considerably more information than many healthcare professionals expect, but the type and amount of information sought should be clarified. 24 There are some significant cultural variations, in particular the involvement of the family in filtering information, which can make disclosure about prognosis and survival especially challenging. 25 Although some physicians may avoid discussing prognosis for fear of upsetting the patient or destroying hope, there is no evidence that increased information about prognosis with sensitive communication is harmful to patients, or that it increases anxiety or distress. [26] [27] [28] [29] [30] [31] For patients wanting quantitative information on life expectancy, providing ranges for worst-case, typical and best-case scenarios is more helpful and conveys more hope than providing a single point estimate of median survival. 32 Ranges for survival scenarios are also more accurate than a single point estimate of expected survival. 17, 33, 34 Oncologists should offer prognostic information to all patients with ABC, allowing patients to determine the type and extent of information required. This recommendation applies to postmenopausal women, to premenopausal women in combination with an LHRH agonist and to men preferably in combination with an LHRH agonist.

The ESMO-MCBS scores for the use of a CDK4/6 inhibitor combined with ET for ABC patients vary according to the setting and drug.

They are the following, with the current available data and follow-up: Maintenance therapy, in this situation, should be carried out with ET alone.

n/a/D 66%

The addition of everolimus to an AI is a valid option for some patients [for pre-and perimenopausal women with OFS/OFA, men (preferably with an LHRH agonist) and postmenopausal women] previously exposed to or naive of (in case CDK4/6 inhibitors are not available) ET, since it significantly prolongs PFS, albeit without evidence of an OS benefit. ESMO-MCBS v1.1 score: 2

The decision to treat must take into account the toxicities associated with this combination, the lack of a statistically significant OS benefit, cost and availability.

Tamoxifen or fulvestrant can also be combined with everolimus.

Adequate prevention, close monitoring and proactive treatment of AEs is needed, particularly in older patients treated with everolimus due to the increased incidence of toxic deaths reported in the BOLERO-2 trial.

Everolimus and CDK4/6 inhibitors should not be used after PD on that specific agent (i.e. beyond progression), outside a clinical trial.

Alpelisib with fulvestrant is a treatment option for patients with PIK3CA-mutated tumours (in exons 9 or 20), previously exposed to an AI and with appropriate HbA1C levels, since it provided about 5 months of benefit in median PFS.

The decision to give alpelisib should take into consideration the inclusion/exclusion criteria in the SOLAR-1 study (i.e. pre-existing diabetes and baseline HbA1c), as well as the toxicity profile of alpelisib.

Its efficacy after exposure to CDK4/6 inhibitors is unknown, since only 6% of patients in the SOLAR-1 trial had been previously treated with those agents. ESMO-MCBS v1.1 score: 3

Patients receiving alpelisib in combination with ET for PIK3CA-mutated ABC should be instructed to take non-sedating antihistamines to prevent rash at the start of therapy. Antihistamines can be discontinued after 4 weeks as the risk for rash is primarily in the first 2 weeks of therapy.

At present, no validated predictive biomarkers other than hormone receptor status exist to identify patients who will/will not benefit from the addition of a CDK4/6 inhibitor or an mTOR inhibitor to ET and none of the studied biomarkers is ready for use in clinical practice. Research efforts must continue.

Alpelisib should only be used in cases of PIK3CA-mutated tumours.

The combination of a nonsteroidal AI and fulvestrant as first-line therapy for postmenopausal patients resulted in significant improvement in both PFS and OS compared with AI alone in one phase III trial and no benefit in a second trial with a similar design. Notably, a suboptimal dose of fulvestrant was used in the study that demonstrated benefit.

Subset analysis suggested that the benefit was limited to patients without prior exposure to adjuvant ET (tamoxifen). Based on these data, combination ET may be offered to some patients with ABC without prior exposure to adjuvant ET in cases where a CDK4/6 inhibitor will not be given. ESMO-MCBS v1.1 score: 2

Comparative data between this combination and a CDK4/6 inhibitor with ET are not available.

No: 60%

Abstain: 2%

The optimal sequence of endocrine-based therapy is uncertain. It depends on which agents were previously used [in the (neo)adjuvant or advanced settings], duration of response to those agents, burden of the disease, patients' preference and availability. Available options for first and second line include AI/fulvestrant + CDK4/6 inhibitor, AI/tamoxifen/fulvestrant + everolimus, fulvestrant + alpelisib (for PIK3CA-mutated tumours), AI, tamoxifen, fulvestrant. This applies to pre-and perimenopausal women with OFS/OFA, men (preferably with an LHRH agonist) and postmenopausal women.

Options for treatment of ER-positive disease beyond second line include single agents not previously used (NSAI, SAI, tamoxifen, fulvestrant, megestrol acetate, low-dose oestrogen). Singleagent abemaciclib is also a potential option.

Challenging a patient with an agent on which the disease previously progressed after an initial response is occasionally considered, but there are no robust data to support this approach. This and baseline HbA1c levels. It is also recommended that patients take non-sedating antihistamines to prevent rash at the start of therapy; 60,61 these can be discontinued after 4

weeks as the risk of rash is primarily in the first 2 weeks of therapy. The ABC panel considers alpelisib a treatment option for patients with ER-positive/HER2-negative PIK3CA-mutated ABC, but in view of the higher benefit provided by CDK4/6 inhibitors, alpelisib plus ET should be used after CDK4/6 plus ET. Only 20 patients (6%) in SOLAR-1 had been previously exposed to a CDK4/6 inhibitor. However, this is a common issue in oncology, where standards of care might change during the course of a trial. Furthermore, the large phase II BYLive trial has shown efficacy of alpelisib after CDK4/6 inhibitor use. 61 The choice of the anti-HER2 agent will depend on country-specific availability, the specific anti-HER2 therapy previously administered and the relapse-free interval. The optimal sequence of all available anti-HER2 therapies is currently unknown.

The optimal duration of anti-HER2 therapy for MBC (i.e. when to stop these agents) is currently unknown.

In patients achieving a complete remission, the optimal duration of maintenance anti-HER2 therapy is unknown and needs to be balanced against treatment toxicity, logistical burden and cost. Stopping anti-HER2 therapy after several years of sustained complete remission may be considered in some patients, particularly if treatment rechallenge is available in case of progression.

Expert opinion/C 93% Patients who have received any type of (neo)adjuvant anti-HER2 therapy should not be excluded from clinical trials for HER2-positive ABC. These patients remain candidates for anti-HER2 therapies.

For highly selected patients a with ER-positive/HER2-positive ABC, for whom ET + anti-HER2 therapy was chosen as first-line therapy, dual anti-HER2 blockade (with either pertuzumab + trastuzumab or lapatinib + trastuzumab) can be used since it provides a benefit in PFS. This decision must be balanced against the higher side effects, higher costs and lack of OS benefit so far, as compared with ET + anti-HER2 monotherapy.

For patients with ER-positive/HER2-positive ABC, for whom ChT + anti-HER2 therapy was chosen as first-line therapy and provided a benefit, it is reasonable to use ET + anti-HER2 therapy as maintenance therapy after stopping ChT, although this strategy has not been studied in randomised trials.

Duration of maintenance therapy should be until progression, unacceptable toxicity or patient request, and needs to be evaluated in clinical trials.

There are no data to decide between single-agent anti-HER2 or dual blockade to combine with maintenance ET after stopping ChT in ER-positive/HER2-positive ABC. There are, however, no data on the use of this combination after progression on pertuzumab or T-DM1.

The combination of neratinib + capecitabine was compared with lapatinib + capecitabine as third line or beyond therapy for HER2-positive ABC, showing a marginal benefit in PFS, and with no significant difference in the co-primary end point of OS. There was no comparator arm with trastuzumab + capecitabine, which had previously been demonstrated to give superior OS to lapatinib + capecitabine. Therefore, the combination of neratinib + capecitabine is not recommended for routine clinical practice.

Additional studies are needed to clearly establish the potential role of this combination in the treatment of brain metastases, as well as the role of neratinib for ABC.

Trastuzumab deruxtecan (DS-8201) showed important activity in a phase II study in heavily compared with patients treated with capecitabine/trastuzumab/placebo. 63 This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation. Importantly, a reduction in the risk of CNS progression or death by 69% was observed in patients with stable brain metastases, while a confirmed objective response rate of 47% and a reduced risk of death by 51% were observed in patients with active brain metastases. 64 Trastuzumab deruxtecan ( No further data to support antiandrogen therapy for triple-negative ABC with expression of the androgen receptor has been published since ABC 4 and therefore it cannot be recommended for routine clinical use outside a clinical trial.

Sacituzumab govitecan-hziy has demonstrated promising activity in advanced lines for triple-negative ABC in a phase I/II study of 108 patients who had received a range of 2-10 prior treatments for metastatic disease. 73 

For ABC patients, results from germline genetic testing have therapeutic implications and should therefore be performed as early as possible.

Appropriate counselling should be provided to patients and their families if a pathogenic germline mutation is found.

At present, only germline mutations in BRCA1/2 have proven clinical utility and therapeutic impact.

Testing for other additional moderate-to high-penetrance genes may be considered, if deemed appropriate by the geneticist/genetic counsellor, in particular because they may have implications for family members. However, it must be clarified to the patient that at present, a mutation in another moderate-/high-penetrance gene has no direct clinical implications for the patients themselves in the setting of ABC.

Expert opinion/C 100%

The therapeutic implications of somatic BRCA1/2 mutations in breast tumours need to be further explored within a research setting and should not be used for decision making in routine clinical practice.

n/a/E 83%

In patients with gBRCA-associated triple-negative ABC or endocrine-resistant ABC previously treated with an anthracycline with or without a taxane (in the adjuvant and/or metastatic setting), a platinum regimen is the preferred ChT option, if not previously administered.

All other ChT recommendations are similar to those for sporadic ABC.

For patients with a gBRCA mutation, single-agent PARPi (olaparib or talazoparib) is a preferred treatment option for those with triple-negative ABC.

In ER-positive gBRCA-associated ABC, the optimal sequence between a PARPi and ET with or without a CDK4/6 inhibitor is unknown. Given the OS benefit seen with CDK4/6 inhibitors, the panel recommends their use before a PARPi. mutations had no impact on response to palbociclib (interaction test between the two regimens P = 0.74). 88 Despite promising preclinical data and statistical trends, the ESCAT scale for ESR1 mutations is tier II. 84 Therefore, ESR1 mutation status assessment is not ready for routine clinical use and is not recommended, either for demonstration of disease progression or selection of hormonal treatment (such as a switch from AI to fulvestrant).

Increased counts of tumour-infiltrating lymphocytes (TILs) are prognostic for survival in TNBC, making this disease a potential target for immunotherapy. 89 Based on the results of the IMpassion-130 trial, 69 acknowledged that patients with tumours between 1% and 10% of ER staining represent a new reporting category, stipulating the lack of data concerning benefit from ET and the proximity to ER-negative breast cancer of this patient group. 99 We recommend that this strategy is also adopted for ABC patients with a low ER-positive status. n/a 100%

Patients with a single or a small number of potentially resectable brain metastases should be treated with surgery or radiosurgery. Radiosurgery is also an option for some unresectable brain metastases.

If surgery/radiosurgery is performed it may be followed by WBRT, but this should be discussed in detail with the patient, balancing the longer duration of intracranial disease control and the risk of neurocognitive effects.

Because patients with HER2-positive ABC and brain metastases can live for several years, consideration of long-term toxicity is important and less toxic local therapy options (e.g.

stereotactic RT) should be preferred to WBRT, when available and appropriate (e.g. in the setting of a limited number of brain metastases).

In patients with HER2-positive ABC who develop brain metastases with stable extracranial disease, systemic therapy should not be changed.

For patients with HER2-positive ABC where brain metastases are the only site of recurrence, the addition of ChT to local therapy is not known to alter the course of the disease and is not recommended.

It is recommended to re-start the anti-HER2 therapy (trastuzumab) if this had been stopped. 

Radionecrosis after stereotactic RT for brain metastases is an uncommon complication that may occur, especially with longer survival and follow-up, and in particular in cases of re-irradiation.

Differential diagnosis with tumour progression is often difficult. Treatment of symptomatic patients with a course of high-dose steroids is the first treatment of choice. If no response, bevacizumab may be used, as an option to decrease the surrounding oedema, usually at a dose of 7.5 mg/kg every 2 weeks for a median of 4 cycles. Prospective randomised trials are needed to further validate this option.

There is no accepted standard of care for breast cancer LMD. The choice of treatment (RT, intra-CSF therapy, systemic therapy, supportive care) should consider prognostic evaluation and multidisciplinary discussion.

Expert opinion 95%

Focal RT should be considered for circumscribed, notably symptomatic lesions. Expert opinion 95%

WBRT can be considered for extensive nodular or symptomatic linear LMD. Expert opinion 95%

Addition of intrathecal to systemic therapy has no OS or QoL advantage and no clinically meaningful effect on CSF progression.

Intrathecal therapy can be considered if systemic disease is stable and there is normal CSF flow, when there is evidence of malignant cells in the CSF (type I LMD). Significant toxicity may occur.

Prospective RCTs of local therapy for breast cancer liver metastases are urgently needed since available evidence comes only from series in highly selected patients. Since there are no 

Malignant pleural effusions require systemic treatment with/without local management.

Thoracentesis for diagnosis should be performed if it is likely that this will change clinical management. False negative results are common.

Drainage is recommended in patients with symptomatic, clinically significant pleural effusion.

Use of an intrapleural catheter or intrapleural administration of talc or drugs (e.g. bleomycin, biological response modifiers) can be helpful.

Clinical trials evaluating the best technique are needed.

Due to the high risk of concomitant distant metastases, patients with chest wall or regional (nodal) recurrence should undergo full restaging, including assessment of chest, abdomen and bone.

Chest wall and regional recurrences should be treated with surgical excision when feasible with limited risk of morbidity.

Locoregional RT is indicated for patients not previously irradiated.

For patients previously irradiated, re-irradiation of all or part of the chest wall may be considered in selected cases.

Expert opinion/C 97% In addition to local therapy (surgery and/or RT), in the absence of distant metastases, the use of systemic therapy (ChT, ET and/or anti-HER2 therapy) should be considered.

ChT after first local or regional recurrence improves long-term outcomes in ER-negative disease and can be used.

ET in this setting improves long-term outcomes for ER-positive disease and should be used. 

Following effective preoperative systemic therapy with or without RT, surgery will be possible in many patients. This will consist of mastectomy with axillary dissection in the majority of cases, but in selected patients with a good response, BCS may be possible.

In patients with axillary low burden of disease at presentation (previously cN0-cN1) with complete response after systemic treatment (ycN0), SLNB can be an option, provided all the recommendations for sentinel node after primary systemic treatment are followed (i.e. dual tracer, clipping/marking positive nodes, minimum of three sentinel nodes). 

Neutropaenia is the most common toxicity associated with CDK4/6 inhibition and is not generally associated with febrile neutropaenia, although an increase in infections has been reported.

Treatment should be delayed until neutrophils have recovered to at least 1000/μl; dose reduction can also be considered.

NIP is an uncommon complication of mTOR inhibition or CDK4/6 inhibition. Patient education is critical to ensure early reporting of respiratory symptoms. Treatment interruption and dose reduction are generally effective for grade 2 symptomatic NIP with the use of systemic steroids and treatment discontinuation for grade 3 or greater toxicity. 

Steroid mouthwash should be used for the prevention of stomatitis induced by mTOR inhibitors (suggested schedule: 0.5 mg/5 ml dexamethasone, 10 ml to swish x 2 minutes, then spit out;

Early intervention is recommended.

For grade >2 stomatitis, delaying treatment until the toxicity resolves and considering lowering the dose of the targeted agent are also recommended.

Mild toothpaste and gentle hygiene are recommended for the treatment of stomatitis.

Consider adding steroid dental paste to treat developing ulcerations. [114] [115] [116] [117] [118] To control hot flushes, valid alternatives are venlafaxine, oxybutynin, gabapentin and clonidine. [119] [120] [121] [122] Sleep disturbances may be treated with melatonin. 123, 124 There is no convincing evidence that phytotherapeutic drugs may improve menopausal symptoms. Possible drug interactions must be considered.

Sexuality is an experience on many levels and is not confined to the act of intercourse.

ABC patients frequently experience impaired sexual health and need specific attention. A recent retrospective study showed that breast cancer patients are more affected than patients with ovarian cancer or healthy controls: decreased or no interest in sexual activity was frequently reported with a significant association to less satisfaction and more discomfort (dyspareunia); however, the lack of desire was not associated with global health status, QoL or the ability to experience orgasms; oestrogen deprivation (gonadotropin-releasing hormone agonists, AIs) seemed to have more impact than tamoxifen. 125 Dyspareunia is often caused by vaginal dryness. The first choice for treating vaginal dryness and soreness are hormone-free lubricants (e.g. water-based gel, hyaluronic acid gel). 126 Expert opinion/C 100% Some complementary therapies have the potential to reduce disease symptom burden and/or side effects of anticancer therapies, and therefore improve the QoL of ABC patients.

Expert opinion/C 100% Evidence suggests beneficial effects of the following methods, which can therefore be used:

• Physical exercise/sport (equivalent to 3-5 hours of moderate walking per week) improves QoL, cardiorespiratory fitness, physical performance and fatigue, and it may also improve DFS and OS.

• MBSR programmes, hypnosis and yoga may improve QoL and fatigue, and help reduce anxiety, distress and some side effects of anticancer therapies.

• Acupuncture may help against ChT-induced nausea and vomiting, fatigue and hot flushes.

The following methods of alternative medicine are not recommended in ABC since available evidence shows no effect at best, or even association with worse outcome: Conference, the ESMO-MCBS will be applied and the result will be made available as an eUpdate to the present guidelines.

We acknowledge that in many areas of the world, some of these guidelines may not be implemented due to the existence of disparities in access. It is the mission of the ABC Global Alliance 143 to fight for better outcomes for all ABC patients around the world. For this goal to be achieved, efforts must continue not only in research but also in public policy to ensure equal access to multidisciplinary, specialised care, including anticancer, palliative and end-oflife care, and full implementation of these guidelines. We emphasise again that reimbursement rules in all countries should be patient-centred and be an incentive, not work against, the clinical implementation of high-quality international guidelines. Clinical trials and consequent approval and reimbursement must not continue to exclude certain groups of patients, such as premenopausal women and men, which keep seeing their treatment options reduced in many countries.

At a time when the world is facing the COVID-19 pandemic, the ABC community must unite to maintain or increase the resources needed to face the ever-rising cancer 'epidemic', which is responsible for 18.1 million new cases and 9.6 million deaths annually worldwide, with half of million deaths annually due to ABC. 12

Communications Ltd; this support was funded by ESMO.

No external funding has been received for the preparation of these guidelines. Production 

G1 Therapeutics and Lilly; receipt of honoraria for symposia lectures from Amgen

CHB reports receipt of honoraria or consultation fees from Boehringer-Ingelheim

Sanofi-Aventis; no personal payments; payment from UpToDate to Asklepios Medicine HB for a chapter on breast cancer prediction. LB reports receipt of grants/research support from Celgene

FC reports receipt of honoraria or consultation fees from Amgen

Novartis and SeaGen; participation in a sponsored speakers' bureau for SeaGen, Pfizer, Lilly and Novartis. NSES reports receipt of grants/research support to institution from Novartis

AE reports receipt of grants/research support from AstraZeneca, Roche, Celltrion, Pfizer and Novartis. LF reports receipt of grants/research support from BMS, GSK, Myriad and Novartis; receipt of honoraria or consultation fees from BMS, AstraZeneca, Teva, Novartis, Eisai, Takeda, Pfizer, Lilly, Genomic Health and Myriad. PAF reports receipt of honoraria or consultation fees from AstraZeneca and Novartis; travel for lecture for Pfizer and Ipsen. KG reports receipt of grants

JG reports receipt of grants/research support from Amgen, Eisai, Genomic Health, Novartis, Pfizer and Roche/Genentech; receipt of honoraria or consultation fees from Daiichi

NUL reports receipt of grants/research support from Genentech and Seattle Genetics; receipt of honoraria or consultation fees from Seattle Genetics, Daiichi Sankyo and Puma. SAM reports receipt of honoraria from Pfizer and Lilly; SN reports receipt of grants/research support from REFERENCES 1

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Global analysis of advanced/metastatic breast cancer: Decade report

SEER data submission, posted to the SEER web site

Improved survival in metastatic breast cancer 1985-2016

Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer

Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer -results from the prospective German TMK cohort study

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

ESMO-Magnitude of Clinical Benefit Scale version 1.1

Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients

End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences

Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients

Communicating prognosis in cancer care: a systematic review of the literature

Prognosis communication in serious illness: perceptions of older patients, caregivers, and clinicians

Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study

Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment

Relationship between cancer patients' predictions of prognosis and their treatment preferences

What do advanced cancer patients know of their disease? A report from Italy

Information needs of patients with cancer: results from a large study in UK cancer centres

Cross-cultural differences in information disclosure evaluated through the EORTC questionnaires

Truth may hurt but deceit hurts more: communication in palliative care

Does it hurt to know the worst?--psychological morbidity, information preferences and understanding of prognosis in patients with advanced cancer

Outcomes of prognostic disclosure: associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer

When the treatment goal is not cure: are cancer patients equipped to make informed decisions?

Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis

Giving honest information to patients with advanced cancer maintains hope

Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience

Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer

The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates

A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for research and regulatory enterprises

Overall survival with ribociclib plus endocrine therapy in breast cancer

Overall survival with ribociclib plus fulvestrant in advanced breast cancer

Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3

The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, erbb2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial

MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

Palbociclib and letrozole in advanced breast cancer

Ribociclib as first-line therapy for HRpositive, advanced breast cancer

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Abemaciclib as initial therapy for advanced breast cancer

Impact of disease progression status on time to deterioration of patient reported health related quality of life in first line ER+ HER2-advanced/metastatic breast cancer patients in the PALOMA-2 study

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Impact of palbociclib plus letrozole on patientreported health-related quality of life: results from the PALOMA-2 trial

Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Overall survival with palbociclib and fulvestrant in advanced breast cancer

Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)

Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer

Management of toxicity to isoform α-specific PI3K inhibitors

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results

4th ESO-ESMO International Consensus Guidelines for advanced breast cancer (ABC 4)

Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer

Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial

Trastuzumab deruxtecan in previously treated HER2-positive breast cancer

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial

A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebocontrolled

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

KEYNOTE-119: Phase 3 study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple-negative breast cancer (mTNBC)

Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded)

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Olaparib for metastatic breast cancer in patients with a germline BRCA mutation

Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

Talazoparib in germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from randomized phase 3 EMBRACA trial. AACR virtual annual meeting

Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

Liquid biopsies: genotyping circulating tumor DNA

Liquid biopsy in breast cancer: A comprehensive review

Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Abstract CT142: Prevalence of PIK3CA mutations in patients with hormone receptor-positive, human epidermal growth factor-2-negative advanced breast cancer from the SOLAR-1 trial

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study

Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer

Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130

College of American Pathologists Clinical Practice Guideline focused update

Low ER+ breast cancer: Is this a distinct group?

Effect of ASCO/CAP guidelines for determining ER status on molecular subtype

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry

Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression

Which threshold for ER positivity? a retrospective study based on 9639 patients

Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and metaanalysis

Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update

Bone health in cancer: ESMO Clinical Practice Guidelines

Leptomeningeal carcinomatosis in patients with breast cancer

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

How we treat patients with leptomeningeal metastases

MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

1st International consensus guidelines for advanced breast cancer (ABC 1)

Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report

Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines

A brief history of the opioid epidemic and strategies for pain medicine

Opioids and cancer pain: Patients' needs and access challenges

Cannabis sativa: Much more beyond Δ(9)-tetrahydrocannabinol

Increased risk of recurrence after hormone replacement therapy in breast cancer survivors

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial

Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial

Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial

Mind-body interventions for vasomotor symptoms in healthy menopausal women and breast cancer survivors. A systematic review

Physical activity for women with breast cancer after adjuvant therapy

Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study

Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis

Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions

Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis

Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603)

A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes

The effect of melatonin on sleep and quality of life in patients with advanced breast cancer

Sexual activity and quality of life in patients after treatment for breast and ovarian cancer

Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?

A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive

Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective, observational study

Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors

Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer

Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials

Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel

American College of Obstetricians and Gynecologists' Committee on Gynecologic Practice

ACOG Committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer

Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial

Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study

Laser-based devices for female genitourinary indications: position statements from the European Society for Sexual Medicine (ESSM)

The Female Sexual Functioning Index (FSFI): evaluation of acceptability, reliability, and validity in women with breast cancer

Development and validation of a sexual relations satisfaction scale in patients with breast cancer -"SEXSAT-Q". Health Qual Life Outcomes

Communication about sexual health in breast cancer: what can we learn from patients' self-report and clinic dialogue? Patient Educ Couns

Patient-reported barriers and facilitators to seeking and accessing support in gynecologic and breast cancer survivors with sexual J o u r n a l P r e -p r o o f problems: a systematic review of qualitative and quantitative studies

Fallowfield's Sexual Activity Questionnaire in women with without and at risk of cancer

Contraception in cancer survivors -an expert review Part I. Breast and gynaecological cancers